MX2021001379A - Compuestos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol y su uso terapeutico. - Google Patents
Compuestos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol y su uso terapeutico.Info
- Publication number
- MX2021001379A MX2021001379A MX2021001379A MX2021001379A MX2021001379A MX 2021001379 A MX2021001379 A MX 2021001379A MX 2021001379 A MX2021001379 A MX 2021001379A MX 2021001379 A MX2021001379 A MX 2021001379A MX 2021001379 A MX2021001379 A MX 2021001379A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- sulfonylmethyl
- methyl
- present
- cyclohexanol
- Prior art date
Links
- YLUKBOJRNYDDQH-UHFFFAOYSA-N 1-methyl-4-[(4-pyridin-2-ylphenyl)sulfonylmethyl]cyclohexan-1-ol Chemical class CC1(CCC(CC1)CS(=O)(=O)C1=CC=C(C=C1)C1=NC=CC=C1)O YLUKBOJRNYDDQH-UHFFFAOYSA-N 0.000 title abstract 2
- -1 4-phenylphenyl Chemical group 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- YFJJFDHHNXNGGX-UHFFFAOYSA-N 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexan-1-ol Chemical class CC1(CCC(CC1)CS(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1)O YFJJFDHHNXNGGX-UHFFFAOYSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 abstract 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 abstract 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención pertenece en general al campo de los compuestos terapéuticos. Más específicamente, la presente invención se refiere a ciertos compuestos sustituidos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol (denominados colectivamente aquí como compuestos CHMSA) que son útiles, por ejemplo, en el tratamiento de trastornos (por ejemplo, enfermedades) que incluyen, por ejemplo, mieloma múltiple, linfoma difuso de células B grandes, leucemia mieloide aguda, leucemia eosinofílica, glioblastoma, melanoma, cáncer de ovario, cáncer resistente a la quimioterapia, cáncer resistente a la radiación, artritis inflamatoria, artritis reumatoide, artritis psoriásica, psoriasis, colitis ulcerosa, enfermedad de Crohn, lupus eritematoso sistémico (LES), nefritis lúpica, asma, enfermedad pulmonar obstructiva crónica (EPOC), enfermedad del hígado graso no alcohólico (NAFLD), esteatohepatitis no alcohólica (NASH), hepatitis autoinmune, hidradenitis supurativa, etc. La presente invención también se refiere a composiciones farmacéuticas que comprenden esos compuestos, y al uso de tales compuestos y composiciones, por ejemplo, en terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813312.4A GB201813312D0 (en) | 2018-08-15 | 2018-08-15 | Compounds and their therapeutic use |
| PCT/EP2019/071917 WO2020035560A1 (en) | 2018-08-15 | 2019-08-15 | 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001379A true MX2021001379A (es) | 2021-05-27 |
Family
ID=63667074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001379A MX2021001379A (es) | 2018-08-15 | 2019-08-15 | Compuestos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol y su uso terapeutico. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11834414B2 (es) |
| EP (1) | EP3837244A1 (es) |
| JP (1) | JP7357057B2 (es) |
| KR (1) | KR20210044802A (es) |
| CN (1) | CN112805270A (es) |
| AU (1) | AU2019322188A1 (es) |
| BR (1) | BR112021002647A2 (es) |
| CA (1) | CA3106860A1 (es) |
| EA (1) | EA202190099A1 (es) |
| GB (1) | GB201813312D0 (es) |
| IL (1) | IL280755B2 (es) |
| MA (1) | MA53224A (es) |
| MX (1) | MX2021001379A (es) |
| SG (1) | SG11202100625TA (es) |
| WO (1) | WO2020035560A1 (es) |
| ZA (1) | ZA202101490B (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| KR101184319B1 (ko) * | 2009-01-29 | 2012-09-19 | 제이엔씨 주식회사 | 배향제 및 이것에 사용되는 액정성 폴리이미드 |
| WO2011066137A1 (en) * | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
| US20120053180A1 (en) * | 2010-08-27 | 2012-03-01 | Chemizon, A Division Of Optomagic Co., Ltd. | Cyclohexane analogues as gpr119 agonists |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| HRP20211877T1 (hr) | 2014-12-17 | 2022-03-04 | Pimco 2664 Limited | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba |
| MX2021010778A (es) | 2015-01-22 | 2022-08-11 | Myokardia Inc | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
-
2018
- 2018-08-15 GB GBGB1813312.4A patent/GB201813312D0/en not_active Ceased
-
2019
- 2019-08-15 MX MX2021001379A patent/MX2021001379A/es unknown
- 2019-08-15 SG SG11202100625TA patent/SG11202100625TA/en unknown
- 2019-08-15 CA CA3106860A patent/CA3106860A1/en active Granted
- 2019-08-15 MA MA053224A patent/MA53224A/fr unknown
- 2019-08-15 AU AU2019322188A patent/AU2019322188A1/en active Pending
- 2019-08-15 EP EP19759309.8A patent/EP3837244A1/en active Pending
- 2019-08-15 CN CN201980064741.7A patent/CN112805270A/zh active Pending
- 2019-08-15 IL IL280755A patent/IL280755B2/en unknown
- 2019-08-15 KR KR1020217006181A patent/KR20210044802A/ko not_active Application Discontinuation
- 2019-08-15 WO PCT/EP2019/071917 patent/WO2020035560A1/en unknown
- 2019-08-15 JP JP2021532520A patent/JP7357057B2/ja active Active
- 2019-08-15 BR BR112021002647-9A patent/BR112021002647A2/pt unknown
- 2019-08-15 EA EA202190099A patent/EA202190099A1/ru unknown
- 2019-08-15 US US17/265,929 patent/US11834414B2/en active Active
-
2021
- 2021-03-04 ZA ZA2021/01490A patent/ZA202101490B/en unknown
-
2023
- 2023-10-24 US US18/493,017 patent/US20240182418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220363642A1 (en) | 2022-11-17 |
| CA3106860A1 (en) | 2020-02-20 |
| KR20210044802A (ko) | 2021-04-23 |
| JP2021534251A (ja) | 2021-12-09 |
| GB201813312D0 (en) | 2018-09-26 |
| IL280755B1 (en) | 2023-07-01 |
| IL280755B2 (en) | 2023-11-01 |
| SG11202100625TA (en) | 2021-02-25 |
| CN112805270A (zh) | 2021-05-14 |
| US20240182418A1 (en) | 2024-06-06 |
| MA53224A (fr) | 2021-06-23 |
| JP7357057B2 (ja) | 2023-10-05 |
| EA202190099A1 (ru) | 2021-07-29 |
| ZA202101490B (en) | 2022-08-31 |
| BR112021002647A2 (pt) | 2021-05-04 |
| EP3837244A1 (en) | 2021-06-23 |
| AU2019322188A1 (en) | 2021-03-18 |
| IL280755A (en) | 2021-04-29 |
| US11834414B2 (en) | 2023-12-05 |
| WO2020035560A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200974T1 (hr) | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova | |
| WO2019055966A3 (en) | PYRIDAZINONES AND METHODS OF USE | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| SA516380328B1 (ar) | مركبات مستبدلة-8،6-دايوكسابيسيكلو[3-2-1]أوكتان-3،2-دايول asgpr كعوامل استهداف | |
| PH12017501989A1 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| ATE501151T1 (de) | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren | |
| PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| SG10201806854XA (en) | Compositions comprising 15-ohepa and methods of using the same | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| PH12019502586A1 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| MX2020004994A (es) | Inhibidores de acss2 y metodos de uso de los mismos. | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| ZA202109179B (en) | Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts | |
| MX2020011225A (es) | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. | |
| MY200912A (en) | Biopharmaceutical Compositions and Related Methods | |
| AU2018320418A1 (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| WO2019126097A8 (en) | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof | |
| MX2023012181A (es) | Anticuerpos anti-cd20 y estructuras car-t. | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| MX2023011725A (es) | Anticuerpos anti-cd19 y estructuras car-t. | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| MX2018011283A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. | |
| MX2021008712A (es) | Derivados heterociclicos. | |
| MX2021001379A (es) | Compuestos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol y su uso terapeutico. | |
| MX2015016914A (es) | N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencensulfonamidas y n-(4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)bencensulfonamidas y su uso terapeutico. |